WO2008024398B1 - Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique - Google Patents

Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique

Info

Publication number
WO2008024398B1
WO2008024398B1 PCT/US2007/018571 US2007018571W WO2008024398B1 WO 2008024398 B1 WO2008024398 B1 WO 2008024398B1 US 2007018571 W US2007018571 W US 2007018571W WO 2008024398 B1 WO2008024398 B1 WO 2008024398B1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
chr
cycloalkyl
cycloalkenyl
ring
Prior art date
Application number
PCT/US2007/018571
Other languages
English (en)
Other versions
WO2008024398A3 (fr
WO2008024398A2 (fr
Inventor
Jean-Michel Vernier
La Rosa Martha Alicia De
Huanming Chen
Jim Zhen Wu
Gary Lee Larson
Ian Wayne Cheney
Original Assignee
Valeant Pharmaceuticals Int
Jean-Michel Vernier
La Rosa Martha Alicia De
Huanming Chen
Jim Zhen Wu
Gary Lee Larson
Ian Wayne Cheney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2007288253A priority Critical patent/AU2007288253B2/en
Priority to CA2661462A priority patent/CA2661462C/fr
Application filed by Valeant Pharmaceuticals Int, Jean-Michel Vernier, La Rosa Martha Alicia De, Huanming Chen, Jim Zhen Wu, Gary Lee Larson, Ian Wayne Cheney filed Critical Valeant Pharmaceuticals Int
Priority to MX2009002002A priority patent/MX2009002002A/es
Priority to BRPI0716715-6A priority patent/BRPI0716715B1/pt
Priority to ES07837199T priority patent/ES2420960T3/es
Priority to PL07837199T priority patent/PL2061465T3/pl
Priority to JP2009525618A priority patent/JP5419691B2/ja
Priority to NZ575652A priority patent/NZ575652A/en
Priority to EP07837199.4A priority patent/EP2061465B1/fr
Priority to DK07837199.4T priority patent/DK2061465T3/da
Publication of WO2008024398A2 publication Critical patent/WO2008024398A2/fr
Publication of WO2008024398A3 publication Critical patent/WO2008024398A3/fr
Publication of WO2008024398B1 publication Critical patent/WO2008024398B1/fr
Priority to IL197161A priority patent/IL197161A/en
Priority to NO20091183A priority patent/NO343575B1/no
Priority to ZA2009/01977A priority patent/ZA200901977B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un composé de formule IA: dans laquelle X = O ou S; Y est O ou S; q = 1 ou 0; et les autres substituants sont tels que definis dans la description. De tels composés peuvent affecter l'ouverture, ou moduler autrement, des canaux potassiques sensibles au voltage. Ils sont potentiellement utiles pour le traitement et la prévention de maladies et de troubles qui sont affectés par l'activation ou la modulation de canaux ioniques au potassium. Une telle condition est constituée par des troubles de crise.
PCT/US2007/018571 2006-08-23 2007-08-22 Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique WO2008024398A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP07837199.4A EP2061465B1 (fr) 2006-08-23 2007-08-22 Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
NZ575652A NZ575652A (en) 2006-08-23 2007-08-22 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MX2009002002A MX2009002002A (es) 2006-08-23 2007-08-22 Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
CA2661462A CA2661462C (fr) 2006-08-23 2007-08-22 Derives de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
ES07837199T ES2420960T3 (es) 2006-08-23 2007-08-22 Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
PL07837199T PL2061465T3 (pl) 2006-08-23 2007-08-22 Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
DK07837199.4T DK2061465T3 (da) 2006-08-23 2007-08-22 Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
AU2007288253A AU2007288253B2 (en) 2006-08-23 2007-08-22 Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
BRPI0716715-6A BRPI0716715B1 (pt) 2006-08-23 2007-08-22 Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
JP2009525618A JP5419691B2 (ja) 2006-08-23 2007-08-22 カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
IL197161A IL197161A (en) 2006-08-23 2009-02-22 Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
NO20091183A NO343575B1 (no) 2006-08-23 2009-03-20 Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
ZA2009/01977A ZA200901977B (en) 2006-08-23 2009-03-20 Derivatives of 4-(in-azacycloalkyl) anilides as potassium channel modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83994106P 2006-08-23 2006-08-23
US60/839,941 2006-08-23

Publications (3)

Publication Number Publication Date
WO2008024398A2 WO2008024398A2 (fr) 2008-02-28
WO2008024398A3 WO2008024398A3 (fr) 2008-06-26
WO2008024398B1 true WO2008024398B1 (fr) 2008-08-14

Family

ID=39107384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018571 WO2008024398A2 (fr) 2006-08-23 2007-08-22 Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique

Country Status (23)

Country Link
US (1) US8293911B2 (fr)
EP (1) EP2061465B1 (fr)
JP (1) JP5419691B2 (fr)
KR (1) KR20090079191A (fr)
CN (1) CN101563085A (fr)
AR (1) AR062508A1 (fr)
AU (1) AU2007288253B2 (fr)
BR (1) BRPI0716715B1 (fr)
CA (1) CA2661462C (fr)
CL (1) CL2007002455A1 (fr)
DK (1) DK2061465T3 (fr)
ES (1) ES2420960T3 (fr)
IL (1) IL197161A (fr)
MX (1) MX2009002002A (fr)
NO (1) NO343575B1 (fr)
NZ (1) NZ575652A (fr)
PL (1) PL2061465T3 (fr)
PT (1) PT2061465E (fr)
RU (1) RU2009110172A (fr)
SG (1) SG174095A1 (fr)
TW (1) TW200827339A (fr)
WO (1) WO2008024398A2 (fr)
ZA (1) ZA200901977B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013060097A1 (fr) 2011-10-25 2013-05-02 中国科学院上海药物研究所 Nouveau composé utilisé comme agoniste des canaux potassiques kcnq, son procédé de préparation et son utilisation

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
WO2006020049A2 (fr) 2004-07-15 2006-02-23 Amr Technology, Inc. Tetrahydroisoquinolines a substitution aryle et heteroaryle et leur utilisation pour bloquer le recaptage de la norepinephrine, la dopamine et la serotonine
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
KR20090079191A (ko) 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서 ４-(ｎ-아자사이클로알킬) 아닐리드의 유도체
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
JP2010511052A (ja) 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010008894A1 (fr) * 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Dérivés de benzyloxy anilide utiles en tant que modulateurs du canal potassique
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
EA020553B1 (ru) 2009-05-12 2014-12-30 Олбани Молекьюлар Рисерч, Инк. 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
CN102971307A (zh) * 2010-07-08 2013-03-13 辉瑞大药厂 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
ES2572908T3 (es) 2011-10-14 2016-06-03 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
RS56168B1 (sr) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
WO2013056034A1 (fr) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia
CN103694163A (zh) * 2012-09-27 2014-04-02 上海先声药物研究有限公司 作为钾通道调节剂的化合物
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
KR20190008411A (ko) * 2016-06-10 2019-01-23 사이플루어 라이프 사이언시즈, 인크 플로오르화 2-아미노-4-(치환된 아미노)페닐 카르밤산염 유도체
US10329516B2 (en) * 2016-12-20 2019-06-25 International Flavors & Fragrances Inc. Organoleptic compounds
US10676437B2 (en) 2017-12-13 2020-06-09 Scifluor Life Sciences, Inc. Fluorinated 4-(substituted amino)phenyl carbamate derivatives
JP2021510699A (ja) 2018-01-10 2021-04-30 アリンキー バイオファーマＡｌｌｉｎｋｙ Ｂｉｏｐｈａｒｍａ テトラヒドロイソキノリン化合物
SG11202011102TA (en) 2018-05-11 2020-12-30 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
WO2020086456A1 (fr) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Formes cristallines de modulateurs des canaux potassiques
EP3917907A1 (fr) 2019-01-29 2021-12-08 Universitá Degli Studi Di Salerno Modulateurs de canaux ioniques potassiques et leurs utilisations
TW202128627A (zh) * 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (fr) * 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methodes de traitement de troubles depressifs
EP4069211A1 (fr) * 2019-12-06 2022-10-12 Xenon Pharmaceuticals Inc. Utilisation d'un agent d'ouverture du canal potassique kv7 pour le traitement de la douleur
CN114057641A (zh) * 2020-08-07 2022-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
US20220288057A1 (en) 2021-02-09 2022-09-15 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
CA3151863C (fr) * 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compose comme regulateur de canal de potassium et preparation et utilisation connexes
CN113698345B (zh) 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
CN118451079A (zh) * 2021-12-31 2024-08-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
CN116478068A (zh) 2022-01-14 2023-07-25 中国科学院上海药物研究所 一种高选择性kcnq4钾通道激动剂、其制备方法和用途
TW202404583A (zh) * 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途
WO2024050389A1 (fr) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Polythérapies comprenant des activateurs des canaux métalliques et des antagonistes des récepteurs nmda
WO2024067819A1 (fr) * 2022-09-30 2024-04-04 上海翰森生物医药科技有限公司 Modulateur de dérivé polycyclique contenant de la pipéridine, son procédé de préparation et son utilisation

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3369315D1 (en) 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
EP0189788B1 (fr) 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Combinaison synergétique de flupirtine et d'anti-phlogistiques non-stéroidaux
ATE43789T1 (de) 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (fr) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (fr) 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
DE69832176T2 (de) 1997-08-08 2006-08-03 Chugai Seiyaku K.K. Arzneimittel gegen diabetes-komplikationen
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
CN1149983C (zh) 1998-12-14 2004-05-19 赛勒吉药物股份有限公司 用于治疗肛门直肠病的组合物和方法
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
BR0008847A (pt) 1999-03-10 2001-12-26 Warner Lambert Co Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
CA2367895A1 (fr) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Composes et techniques de modulation des recepteurs des oestrogenes
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
CA2378613C (fr) 1999-07-06 2007-10-02 Eli Lilly And Company Antagonistes selectifs du recepteur iglur5 utilises dans le traitement de la migraine
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
CA2378243C (fr) 1999-08-04 2012-05-15 Icagen, Inc. Procedes therapeutiques ou prophylactiques de la douleur et de l'anxiete
CA2378241A1 (fr) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides comme ouvreurs de canaux potassiques
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
HUP0401750A2 (hu) * 2001-05-31 2004-12-28 Bristol-Myers Squibb Company Cinnamidszármazékok mint KCNQ káliumcsatorna-modulátorok és ezeket tartalmazó gyógyszerkészítmények
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (fr) 2002-02-12 2003-08-21 Pfizer Inc. Composes non-peptidiques influant sur l'action de la gnrh
AUPS110302A0 (en) * 2002-03-14 2002-04-18 Biomolecular Research Institute Limited Novel chalcone derivatives and uses thereof
JP2005526137A (ja) 2002-05-17 2005-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノテトラリン−誘動尿素のバニロイドｖｒ１受容体調節剤
WO2003106454A1 (fr) * 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd Derives de 1h-isoquinoline-oxazolidinone, et leur utilisation comme agents antibacteriens
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
DE60335028D1 (de) 2002-12-23 2010-12-30 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
US7368472B2 (en) 2002-12-27 2008-05-06 H. Lundbeck A/S 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
EP1606247A1 (fr) 2003-03-14 2005-12-21 H. Lundbeck A/S Derives d'aniline substitues
BRPI0408437A (pt) 2003-03-21 2006-04-04 Lundbeck & Co As H derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
AU2004233941A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
RS20050868A (en) 2003-05-27 2007-08-03 Altana Pharma Ag., Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
WO2005025511A2 (fr) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
CA2539853C (fr) * 2003-09-23 2011-04-19 Merck & Co., Inc. Inhibiteurs du canal potassique isoquinolinone
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP1737852A2 (fr) 2004-04-13 2007-01-03 Icagen, Inc. Pyridines polycycliques en tant que modulateurs de canal ionique du potassium
EP1748776A1 (fr) 2004-05-03 2007-02-07 Duke University Compositions influant sur la perte de poids
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1813285A4 (fr) 2004-11-19 2010-06-09 Kissei Pharmaceutical Agent préventif ou thérapeutique pour la douleur neuropathique
EP1688141A1 (fr) 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
WO2006092143A1 (fr) 2005-03-03 2006-09-08 H. Lundbeck A/S Derives de pyridine substitues
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
KR20090079191A (ko) 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서 ４-(ｎ-아자사이클로알킬) 아닐리드의 유도체
JP2010511052A (ja) 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013060097A1 (fr) 2011-10-25 2013-05-02 中国科学院上海药物研究所 Nouveau composé utilisé comme agoniste des canaux potassiques kcnq, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
CN101563085A (zh) 2009-10-21
PL2061465T3 (pl) 2014-03-31
EP2061465A2 (fr) 2009-05-27
ZA200901977B (en) 2010-02-24
EP2061465B1 (fr) 2013-04-10
NZ575652A (en) 2011-08-26
IL197161A (en) 2015-07-30
CA2661462A1 (fr) 2008-02-28
JP5419691B2 (ja) 2014-02-19
IL197161A0 (en) 2009-12-24
AR062508A1 (es) 2008-11-12
RU2009110172A (ru) 2010-09-27
PT2061465E (pt) 2013-07-15
BRPI0716715A2 (pt) 2013-09-03
DK2061465T3 (da) 2013-07-08
US8293911B2 (en) 2012-10-23
US20080139610A1 (en) 2008-06-12
JP2010501568A (ja) 2010-01-21
WO2008024398A3 (fr) 2008-06-26
SG174095A1 (en) 2011-09-29
MX2009002002A (es) 2009-07-22
WO2008024398A2 (fr) 2008-02-28
NO20091183L (no) 2009-05-08
BRPI0716715B1 (pt) 2021-07-06
CA2661462C (fr) 2015-09-29
ES2420960T3 (es) 2013-08-28
CL2007002455A1 (es) 2008-04-18
NO343575B1 (no) 2019-04-08
AU2007288253A1 (en) 2008-02-28
EP2061465A4 (fr) 2011-03-16
KR20090079191A (ko) 2009-07-21
AU2007288253B2 (en) 2013-05-02
TW200827339A (en) 2008-07-01

Similar Documents

Publication Publication Date Title
WO2008024398B1 (fr) Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
CA2565660A1 (fr) Composes aryl- ou heteroarylamides ortho-substitues
EP2172472A3 (fr) Dérivés d'acides aminophosphoniques et leurs sels d'addition en tant que modulateurs du récepteur S1P
JP2009532453A5 (fr)
WO2005105732A8 (fr) Composes methylaryl- ou heteroarylamides substitues
IL165829A0 (en) N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
EP2743268A3 (fr) Composés cycliques condensés comme modulateurs du recepteur GPR40
HK1084026A1 (en) Compounds for the treatment of metabolic disorders
WO2006136837A3 (fr) Composes pharmaceutiques
EP1798226A4 (fr) Derive de traizol
MY152176A (en) Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
WO2004073611A3 (fr) Composés pour le traitement de troubles métaboliques
WO2008108380A3 (fr) Composés de pyrrole
DK1045830T3 (da) Alfa-aminoamidderivater, der er anvendelige som analgetiske midler
RU2010107169A (ru) Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого
WO2007074078A3 (fr) Derives aryl-isoxazol-4-yl-imidazo[1,5-a] pyridine
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
WO2004098496A3 (fr) Composes destines au traitement de troubles metaboliques
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
BRPI0416228A (pt) uso de inibidores glucosidade para terapia de mucovisidose
WO2006127133B1 (fr) Composes pour le traitement de troubles metaboliques
WO2004093806A3 (fr) Composes pour le traitement de troubles metaboliques
UA88772C2 (ru) Соединения для лечения расстройств метаболизма
WO2006124865A3 (fr) Biaryles utiles en tant que modulateurs des canaux ioniques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780039265.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837199

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2661462

Country of ref document: CA

Ref document number: 2009525618

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 197161

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002002

Country of ref document: MX

Ref document number: 12009500357

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007288253

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 575652

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1085/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009110172

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A20090426

Country of ref document: BY

Ref document number: 2007837199

Country of ref document: EP

Ref document number: 1020097005943

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007288253

Country of ref document: AU

Date of ref document: 20070822

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0716715

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090225